LNSR · Lensar, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.43M | - | $14.32M | $13.94M | $14.16M | - | $13.54M | $12.64M | $10.59M | - |
| Cost of Revenue | $7.05M | - | $8.28M | $6.91M | $7.03M | - | $7.27M | $5.82M | $4.92M | - |
| Gross Profit | $6.38M | - | $6.04M | $7.02M | $7.13M | - | $6.27M | $6.81M | $5.66M | - |
| R&D | $1.39M | - | $1.37M | $1.43M | $1.53M | - | $1.20M | $1.35M | $1.44M | - |
| SG&A | $2.53M | - | $12.02M | $11.66M | $11.15M | - | $6.08M | $6.78M | $6.80M | - |
| Total Operating Expenses | $4.14M | - | $13.62M | $12.09M | $8.51M | - | - | - | - | - |
| D&A | $904.0K | - | - | - | $844.0K | - | - | - | $647.0K | - |
| Operating Income | $2.24M | - | ($7.58M) | ($6.29M) | ($5.79M) | - | ($1.25M) | ($5.28M) | ($2.85M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | $36.33M | - | ($3.71M) | ($1.76M) | ($27.34M) | - | ($1.50M) | ($9.04M) | ($2.16M) | - |
| EPS - Basic | $1.56 | - | ($0.31) | ($0.15) | ($2.32) | - | ($0.13) | ($0.79) | ($0.19) | - |
| EPS - Diluted | $0.00 | - | ($0.31) | ($0.15) | ($2.32) | - | ($0.13) | ($0.79) | ($0.19) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.49M | $12.97M | $7.64M | $7.15M | $19.55M | $16.26M | $10.44M | $8.29M | $13.96M | $20.62M |
| Accounts Receivable | $4.90M | $6.38M | $5.90M | $4.99M | $6.88M | $6.08M | $4.37M | $5.89M | $4.02M | $4.00M |
| Inventory | $23.10M | $21.52M | $20.60M | $19.24M | $15.32M | $11.43M | $14.89M | $17.93M | $17.82M | $15.69M |
| Accounts Payable | $10.10M | $18.98M | $14.79M | $11.31M | $7.75M | $6.00M | $3.87M | $4.12M | $4.12M | $4.01M |
| Current Assets | $42.40M | $46.77M | $44.43M | $45.87M | $49.19M | $41.98M | $39.40M | $40.23M | $42.44M | $46.44M |
| Total Assets | $66.22M | $71.43M | $70.20M | $70.41M | $72.96M | $66.30M | $62.02M | $61.41M | $66.13M | $69.58M |
| Current Liabilities | $17.80M | $40.57M | $35.73M | $30.09M | $27.17M | $15.00M | $11.68M | $10.37M | $10.45M | $11.63M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $41.65M | $83.67M | $82.33M | $79.68M | $81.32M | $47.65M | $25.50M | $23.98M | $20.55M | $22.41M |
| Stockholders' Equity | $10.79M | ($26.02M) | ($25.91M) | ($23.05M) | ($22.14M) | $4.86M | $22.74M | $23.64M | $31.84M | $33.43M |
| Retained Earnings | ($141.24M) | ($177.57M) | ($176.12M) | ($172.40M) | ($170.64M) | ($143.29M) | ($124.59M) | ($123.09M) | ($114.05M) | ($111.89M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.27M) | - | - | - | ($6.94M) | - | - | - | ($5.31M) | - |
| Investing Cash Flow | $4.00M | - | - | - | $531.0K | - | - | - | ($1.23M) | - |
| Financing Cash Flow | ($209.0K) | - | - | - | $9.69M | - | - | - | ($130.0K) | - |
| CapEx | - | - | - | - | $6.0K | - | - | - | $20.0K | - |
| Free Cash Flow | - | - | - | - | ($6.94M) | - | - | - | ($5.33M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 47.5% | - | 42.2% | 50.4% | 50.3% | - | 46.3% | 53.9% | 53.5% | - |
| Operating margin | 16.7% | - | -52.9% | -45.1% | -40.9% | - | -9.2% | -41.8% | -26.9% | - |
| EBITDA margin | 23.4% | - | - | - | -34.9% | - | - | - | -20.8% | - |
| Net margin | 270.6% | - | -25.9% | -12.7% | -193.1% | - | -11.1% | -71.6% | -20.4% | - |
| Free cash flow margin | - | - | - | - | -49.0% | - | - | - | -50.3% | - |
| FCF / Net income | - | - | - | - | 0.25 | - | - | - | 2.47 | - |
| R&D / Revenue | 10.3% | - | 9.5% | 10.2% | 10.8% | - | 8.9% | 10.7% | 13.6% | - |
| SG&A / Revenue | 18.8% | - | 84.0% | 83.7% | 78.7% | - | 44.9% | 53.7% | 64.2% | - |
| Effective tax rate | 0.0% | - | - | - | - | - | - | - | - | - |
| Return on assets | 54.9% | - | -5.3% | -2.5% | -37.5% | - | -2.4% | -14.7% | -3.3% | - |
| Return on equity | 336.7% | - | 14.3% | 7.7% | 123.5% | - | -6.6% | -38.2% | -6.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.38 | 1.15 | 1.24 | 1.52 | 1.81 | 2.80 | 3.37 | 3.88 | 4.06 | 3.99 |
| Quick ratio | 1.08 | 0.62 | 0.67 | 0.88 | 1.25 | 2.04 | 2.10 | 2.15 | 2.36 | 2.64 |
| Cash ratio | 0.70 | 0.32 | 0.21 | 0.24 | 0.72 | 1.08 | 0.89 | 0.80 | 1.34 | 1.77 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 6.14 | -2.75 | -2.71 | -3.05 | -3.30 | 13.64 | 2.73 | 2.60 | 2.08 | 2.08 |
| Liabilities / Assets | 0.63 | 1.17 | 1.17 | 1.13 | 1.11 | 0.72 | 0.41 | 0.39 | 0.31 | 0.32 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.20 | 0.20 | 0.19 | - | 0.22 | 0.21 | 0.16 | - |
| Inventory turnover | 0.31 | - | 0.40 | 0.36 | 0.46 | - | 0.49 | 0.32 | 0.28 | - |
| Days sales outstanding | 133d | - | 150d | 131d | 177d | - | 118d | 170d | 139d | - |
| Days inventory outstanding | 1197d | - | 908d | 1016d | 795d | - | 747d | 1124d | 1321d | - |
| Days payable outstanding | 523d | - | 652d | 598d | 402d | - | 194d | 258d | 305d | - |
| Cash conversion cycle | 807d | - | 406d | 549d | 570d | - | 671d | 1036d | 1154d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 8.5x | - | - | - | - | - | 2.3x | 2.2x | 1.2x | - |
| P / S | 6.8x | - | 10.4x | 11.3x | 11.7x | - | 3.9x | 4.1x | 3.7x | - |
| EV / EBITDA | 25.3x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -5.2% | - | 5.7% | 10.3% | 33.7% | - | 38.2% | 5.2% | 28.3% | - |
| Revenue CAGR (3y) | 17.6% | - | 22.7% | 20.1% | 14.9% | - | 17.8% | 35.8% | 21.5% | - |
| Revenue CAGR (5y) | 17.9% | - | 14.9% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -10.4% | - | -3.7% | 3.1% | 25.8% | - | 28.5% | 0.8% | 31.1% | - |
| Operating income growth (YoY) | - | - | -508.8% | -19.1% | -103.2% | - | 39.0% | -84.2% | 34.6% | - |
| Net income growth (YoY) | - | - | -147.2% | 80.5% | -1167.7% | - | - | -3.3% | 49.5% | - |
| EPS growth (YoY) | - | - | -138.5% | 81.0% | -1121.1% | - | 43.5% | 2.5% | 52.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -30.4% | - | - | - | 20.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | -85.5% | -37.5% | -27.7% | -19.3% | -20.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$51.66M totalProduct$45.93M · 88.9%
Service$5.73M · 11.1%
Geographic
$51.66M totalUS$34.31M · 66.4%
Europe$8.43M · 16.3%
Asia Excluding South Korea$8.02M · 15.5%
KR$658.0K · 1.3%
Other Geographical Region$238.0K · 0.5%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing LENSAR against the 5 most active filers in the same SIC group.